Benzothiophene nucleus in target-directed anti-cancer drug discovery

The benzo[b]thiophene scaffold has emerged as a privileged chemotype in target-directed anticancer drug discovery because of its structural versatility and distinctive sulfur-centered interactions that support selective target binding. This review provides a focused, mechanism-based analysis of benzothiophene derivatives developed as anti-cancer agents, emphasizing compounds with experimentally validated molecular targets and confirmed cellular activity rather than nonspecific cytotoxins. Benzothiophenes have been designed to modulate diverse oncogenic targets, including receptor and non-receptor kinases, STAT3, estrogen receptor pathways, epigenetic regulators, metabolic enzymes, tubulin, and DNA-associated systems. Many derivatives show nanomolar potency, pathway-selective effects, in vivo anti-tumor activity, improved selectivity, and enhanced metabolic stability. Raloxifene remains the only benzothiophene-based drug approved for an oncological indication, highlighting both the scaffold's clinical promise and the translational barriers that have limited its broader therapeutic advancement. This review also examines key structure-activity relationships, binding determinants, and optimization strategies guiding benzothiophene-based anti-cancer therapeutics.